MEGAPORT-LIMITED
14.12.2021 23:02:07 CET | Business Wire | Press release
Megaport Limited (ASX: MP1) ("Megaport"), a global leading Network as a Service (NaaS) provider, today announces the availability of VMware SD-WAN on Megaport Virtual Edge (MVE). VMware SD-WAN’s will be interoperable with MVE to enable branch-to-cloud connectivity on Megaport’s global Software Defined Network (SDN).
Optimising VMware SD-WAN Connectivity
Many businesses have embraced SD-WAN and internet connections as a means of simplifying their IT connectivity. With VMware SD-WAN available on MVE, customers can host localised virtual SD-WAN controllers on Megaport’s global platform and reduce the distance data traverses over internet paths from branch locations to critical services in public or private clouds and even other branch locations.
Once connected, VMware customers can access Megaport’s leading ecosystem of more than 700 enabled data centres worldwide and over 360 service providers, including 220+ cloud on-ramps from the world's leading clouds such as Alibaba Cloud, AWS, Google Cloud, Microsoft Azure, IBM Cloud, Oracle Cloud, and Salesforce.
VMware SD-WAN on MVE Highlights:
- Reduced cloud egress costs to cloud on-ramps when compared to internet rates.
- Globally distributed for localised connections.
- Point-and-click network provisioning to support interconnection between branch locations, data centres, cloud providers, and IT services.
- Real-time provisioning of virtual network infrastructure and interconnections.
- No hardware to ship, install, or manage.
- Unified end-to-end network provisioning and management to transform legacy networks.
- More secure, multi-cloud connections to more than 360 service providers, 700+ enabled data centres, and 220+ cloud interconnect points.
Craig Connors, vice president and general manager at VMware, said, “VMware SD-WAN in combination with Megaport Virtual Edge offers customers more choice for simplifying WAN operations, reliable network performance for business-critical applications, and easier adoption of hybrid cloud and multi-cloud, while reducing latency to cloud workloads.”
Transforming Networking at the Edge
MVE is a globally distributed compute and network service in one. The compute aspect of the service enables customers to host NFV instances in locations where they need them, on demand, and manage them in a point-and-click manner. On the network side, MVE’s built-in transit gateway provides a highly scalable access point for connecting networks, via the public internet, to Megaport’s private SDN. Virtualised devices hosted on MVE can utilise the transit gateway to create connections between the Megaport SDN and their own networks, including branch locations, data centres, and private clouds.
MVE is available in 24 metros across North America, Asia-Pacific, and Europe. This allows customers more flexibility to deploy virtual devices near concentrations of users to localise traffic and optimise data termination for performance.
“As enterprises and service providers rapidly adopt SD-WAN technology to improve edge network connectivity, the ability for Megaport customers to easily, and in minutes, ‘spin up’ VMware SD-WAN edge routers around the world on our platform is a big enabler for global organisations,” said Vincent English, CEO of Megaport. “Having VMware SD-WAN in Megaport’s global Software Defined Network allows our customers to optimise their SD-WAN connectivity to improve overall network and application performance at a fraction of the cost of legacy methods.”
For more information about Megaport Virtual Edge, please visit https://www.megaport.com/mve .
For more information about VMware SD-WAN, learn more at https://sdwan.vmware.com/ .
VMware and VMware SD-WAN are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
About Megaport
Megaport is a leading provider of Network as a Service (NaaS) solutions. The company’s global Software Defined Network (SDN) helps businesses rapidly connect their network to services via an easy-to-use portal or our open API. Megaport offers agile networking capabilities that reduce operating costs and increase speed to market compared to traditional networking solutions. Megaport partners with the world’s top cloud service providers, including AWS, Microsoft Azure, and Google Cloud, as well as the largest data centre operators, systems integrators and managed service providers in the world. Megaport is an ISO/IEC 27001-certified company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom